Method of inducing the production of antibodies to HIV

Details Method of inducing the production of antibodies to HIV Method of inducing the production of antibodies to HIV

2006-07-04

2006-07-04

Stucker, Jeffrey (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Conjugate or complex

C424S188100, C424S192100, C424S193100, C424S208100

Reexamination Certificate

active

07070787

ABSTRACT:
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.

REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5843454 (1998-12-01), Devico et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2002/0086283 (2002-07-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0001851 (2004-01-01), Haynes et al.
patent: 2004/0086506 (2004-05-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 94/15638 (1994-07-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 00/08043 (2000-02-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/024149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004/009785 (2004-01-01), None
patent: WO 2004/075850 (2004-09-01), None
patent: WO 2005/016952 (2005-02-01), None
patent: WO 2005/028625 (2005-03-01), None
Abaza et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”, Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp. 433-444.
Fahey et al. “Status of immune-based therapies in HIV infection and AIDS”, Clinical and Experimental Immunology, vol. 88 (1992), pp. 1-5.
Fox “No winners against AIDS”, Bio/Technology, vol. 12 (Feb. 1994), p. 128.
Cohen et al. “Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge”, Proceedings of the National Academy of Sciences of the United States of America, vol. 96, Issue 19(Sep. 14, 1999), pp. 10842-10847.
Cruse et al. Illustrated Dictionary of Immunology (Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul, Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250, 1311-1312, and 1387. QR181.F84.
Riffkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 from Dichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Devico et al, “Covalently Crosslinked Complexes of Human Immunodeficiency Virus Type 1 (HIV-1) gp120 and CD4 Receptor Elicit a Neutralizing Immune Response That Includes Antibodies Selective for Primary Virus Isolates”, Virology 218:258-263 (1996).
Zhang et al, “Antibody 17b Binding at the Coreceptor Site Weakens the Kinetics of the Interaction of Envelope Glycoprotein gp120 with CD4”, Biochemistry 40:1662-1670 (2001).
Rimsky et al, “Determinants of Human Immunodeficiency Virus Type 1 Resistance of gp41-Derived Inhibitory Peptides”, Journal of Virology 72(2):986-993 (1998).
Zhang et al, “Conformational Changes of gp120 in Epitopes near the CCR5 Binding Site Are Induced by CD4 and a CD4 Miniprotein Mimetic”, Biochemistry 38:9405-9416 (1999).
Liao et al, “Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins”, Journal of Virology 78(10):5270-5278 (2004).
Boots et al, “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries”, AIDS Research and Human Retroviruses 13(18):1549-1559 (1997).
U.S. Appl. No. 60/503,460 filed Sep. 17, 2003 and U.S. Appl. No. 60/604,722 filed Aug. 27, 2004 (see attached copy of WO 2005/028625).
U.S. Appl. No. 10/518,523 filed Dec. 21, 2004 (U.S. National Phase of WO 2004/009785 see above).
U.S. Appl. No. 10/973,977 filed Oct. 27, 2004.
U.S. Appl. No. 10/973,475 filed Oct. 27, 2004.
U.S. Appl. No. 60/625,720 filed Nov. 8, 2004.
Zhang et al, “Antibody 17b Binding at the Coreceptor Site Weakens the Kinetics of the Interaction of Envelope Glycoprotein gp120 with CD4”, Biochemistry 40:1662-1670 (2001).
Zhang et al, “Conformational Changes of gp120 in Epitopes near the CCR5 Binding Site Are Induced by CD4 and a CD4 Miniprotein Mimetic”, Biochemistry 38:9405-9416 (1999).
Liao et al, “Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins”, Journal of Virology 78(10):5270-5278 (2004).
Stamatatos et al, “Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates”, AIDS Research and Human Retroviruses 16(10):981-994 (2000).
Hoffman et al, “Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein”, Proc. Natl. Acad. Sci. USA 96:6359-6364 (1999).
Golding et al, “Phorbol Ester-Induced Down Modulation of Tailless CD4 Receptors Requires Prior Binding of gp120 and Suggests a Role for Accessory Molecules”, Journal of Virology 69(10):6140-6148 (1995).
Kwong et al, “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody”, Nature 393:648-659 (1998).
Wyatt et al, “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding”, Journal of Virology 69(9):5723-5733 (1995).
Furata et al, “Capture of an early fusion-active conformation of HIV-1 gp41”, Nature Struct. Biol. 5:276 (1998).
LaCasse et al, “Fusion-Competent Vaccines” Broad Neutralization of Primary Isolates of HIV, Science 283:357 (1997).
Boots et al, “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries”, AIDS Research and Human Retroviruses 13(18):1549-1559 (1997).
Bieniasz et al, “HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor”, The EMBO Journal 16(10):2599-2609 (1997).
Wild et al, “Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex”, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994).
Collman et al, “An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1”, Journal of Virology 66(12):7517-7521 (1992).
Alam et al, “T-cell-receptor affinity and thymocyte positive selection”, Letters to Nature 381:616-620 (1996).
O'Shannessy et al, “Immobilization Chemistries Suitable for Use in the BIAcore Surface Plasmon Resonance Detector”, Analytical Biochemistry 205:132-136 (1992).
Mascola et al, “Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type I”, J. Infect. Dis. 173:340-348 (1996).
Rizzuto et al, “A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding”, Science 280:1949-1953 (1998).
Wyatt et al, “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding

Affiliated with

Also associated with

Rating

Method of inducing the production of antibodies to HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inducing the production of antibodies to HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inducing the production of antibodies to HIV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3578254